October 2012 | Oncology & Biotech News

November 13, 2012

In September 2012 the new joint Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital was established, bringing together basic, translational, and clinical researchers to operate within a vast, collaborative infrastructure.

November 09, 2012

The last year of life is associated with high health expenditures in the United States, and the costs are increasingly focused on patients' last few months.

November 08, 2012

Patients receiving a daily regimen of L-carnitine did not experience improved fatigue versus placebo on the widely validated Brief Fatigue Inventory.

November 07, 2012

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

November 07, 2012

Now that several effective agents are FDA-approved for the treatment of CML, it is important to ascertain whether a treatment is working, and if not, how to respond in terms of switching treatment.

November 06, 2012

Men who take the dietary antioxidant beta-carotene while they are undergoing radiation therapy for prostate cancer do not have an increased risk of prostate cancer death or metastases.

November 06, 2012

Stakeholders weigh in on evidence-based pathway approach designed to decrease practice variation, improve outcomes, and reduce cost.

November 06, 2012

The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.

November 05, 2012

Transplant remains the cornerstone of treatment for relapsed/refractory Hodgkin lymphoma, but some new approaches are on the horizon and may also prove to be valid options.

October 31, 2012

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

October 31, 2012

Community oncologists must weigh multiple factors when deciding to consolidate or remain independent.

October 29, 2012

Men with increased cholesterol levels may have an elevated risk of developing high-grade prostate cancer.

October 29, 2012

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

October 26, 2012

For those who treat overweight or obese cancer patients, choosing doses of chemotherapy can be a sweat-producing endeavor.

October 25, 2012

Computer-aided computed tomographic colonography that does not require a laxative preparation nearly rivals conventional optical colonoscopy for identifying asymptomatic adults with adenomas.

October 23, 2012

New data from a study sponsored by the National Institutes of Health appear to have proven that there is an inexpensive and relatively simple approach to reducing the incidence of most cancers that afflict men: Take a multivitamin daily.

October 23, 2012

Treatment with the investigational agent dacomitinib improved PFS when compared with erlotinib in patients with non–small cell lung cancer experiencing progression during chemotherapy.